| Product Code: ETC7635310 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Ireland Neuroblastoma Drug Market Overview |
3.1 Ireland Country Macro Economic Indicators |
3.2 Ireland Neuroblastoma Drug Market Revenues & Volume, 2021 & 2031F |
3.3 Ireland Neuroblastoma Drug Market - Industry Life Cycle |
3.4 Ireland Neuroblastoma Drug Market - Porter's Five Forces |
3.5 Ireland Neuroblastoma Drug Market Revenues & Volume Share, By Mechanism of Action Type, 2021 & 2031F |
3.6 Ireland Neuroblastoma Drug Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.7 Ireland Neuroblastoma Drug Market Revenues & Volume Share, By Diagnosis Type, 2021 & 2031F |
3.8 Ireland Neuroblastoma Drug Market Revenues & Volume Share, By Treatment Type, 2021 & 2031F |
3.9 Ireland Neuroblastoma Drug Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.10 Ireland Neuroblastoma Drug Market Revenues & Volume Share, By End- Users, 2021 & 2031F |
4 Ireland Neuroblastoma Drug Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing incidence of neuroblastoma cases in Ireland |
4.2.2 Technological advancements in neuroblastoma drug development |
4.2.3 Growing investments in research and development for neuroblastoma treatments |
4.3 Market Restraints |
4.3.1 Stringent regulatory processes for drug approvals in Ireland |
4.3.2 High costs associated with neuroblastoma drug development and treatment |
4.3.3 Limited availability of specialized healthcare facilities for neuroblastoma patients in Ireland |
5 Ireland Neuroblastoma Drug Market Trends |
6 Ireland Neuroblastoma Drug Market, By Types |
6.1 Ireland Neuroblastoma Drug Market, By Mechanism of Action Type |
6.1.1 Overview and Analysis |
6.1.2 Ireland Neuroblastoma Drug Market Revenues & Volume, By Mechanism of Action Type, 2021- 2031F |
6.1.3 Ireland Neuroblastoma Drug Market Revenues & Volume, By Alkylating agents, 2021- 2031F |
6.1.4 Ireland Neuroblastoma Drug Market Revenues & Volume, By Antimetabolites, 2021- 2031F |
6.1.5 Ireland Neuroblastoma Drug Market Revenues & Volume, By Antibiotics, 2021- 2031F |
6.1.6 Ireland Neuroblastoma Drug Market Revenues & Volume, By Microtubule Inhibitors, 2021- 2031F |
6.1.7 Ireland Neuroblastoma Drug Market Revenues & Volume, By Monoclonal Antibodies, 2021- 2031F |
6.2 Ireland Neuroblastoma Drug Market, By Drug Type |
6.2.1 Overview and Analysis |
6.2.2 Ireland Neuroblastoma Drug Market Revenues & Volume, By Cyclophosphamide, 2021- 2031F |
6.2.3 Ireland Neuroblastoma Drug Market Revenues & Volume, By Cisplatin, 2021- 2031F |
6.2.4 Ireland Neuroblastoma Drug Market Revenues & Volume, By Vincristine, 2021- 2031F |
6.2.5 Ireland Neuroblastoma Drug Market Revenues & Volume, By Doxorubicin, 2021- 2031F |
6.2.6 Ireland Neuroblastoma Drug Market Revenues & Volume, By Etoposide, 2021- 2031F |
6.2.7 Ireland Neuroblastoma Drug Market Revenues & Volume, By Topotecan, 2021- 2031F |
6.3 Ireland Neuroblastoma Drug Market, By Diagnosis Type |
6.3.1 Overview and Analysis |
6.3.2 Ireland Neuroblastoma Drug Market Revenues & Volume, By Physical Test, 2021- 2031F |
6.3.3 Ireland Neuroblastoma Drug Market Revenues & Volume, By Urine and Blood Test, 2021- 2031F |
6.3.4 Ireland Neuroblastoma Drug Market Revenues & Volume, By Imaging Test, 2021- 2031F |
6.3.5 Ireland Neuroblastoma Drug Market Revenues & Volume, By Tissue Sample Testing, 2021- 2031F |
6.3.6 Ireland Neuroblastoma Drug Market Revenues & Volume, By Bone Marrow Sample Testing, 2021- 2031F |
6.4 Ireland Neuroblastoma Drug Market, By Treatment Type |
6.4.1 Overview and Analysis |
6.4.2 Ireland Neuroblastoma Drug Market Revenues & Volume, By Surgery, 2021- 2031F |
6.4.3 Ireland Neuroblastoma Drug Market Revenues & Volume, By Chemotherapy, 2021- 2031F |
6.4.4 Ireland Neuroblastoma Drug Market Revenues & Volume, By Radiotherapy, 2021- 2031F |
6.4.5 Ireland Neuroblastoma Drug Market Revenues & Volume, By Immunotherapy, 2021- 2031F |
6.4.6 Ireland Neuroblastoma Drug Market Revenues & Volume, By Bone Marrow transplantation, 2021- 2031F |
6.4.7 Ireland Neuroblastoma Drug Market Revenues & Volume, By Retinoid Therapy, 2021- 2031F |
6.5 Ireland Neuroblastoma Drug Market, By Route of Administration |
6.5.1 Overview and Analysis |
6.5.2 Ireland Neuroblastoma Drug Market Revenues & Volume, By Oral, 2021- 2031F |
6.5.3 Ireland Neuroblastoma Drug Market Revenues & Volume, By Intravenous and others, 2021- 2031F |
6.6 Ireland Neuroblastoma Drug Market, By End- Users |
6.6.1 Overview and Analysis |
6.6.2 Ireland Neuroblastoma Drug Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.6.3 Ireland Neuroblastoma Drug Market Revenues & Volume, By Homecare, 2021- 2031F |
6.6.4 Ireland Neuroblastoma Drug Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.6.5 Ireland Neuroblastoma Drug Market Revenues & Volume, By Others, 2021- 2031F |
7 Ireland Neuroblastoma Drug Market Import-Export Trade Statistics |
7.1 Ireland Neuroblastoma Drug Market Export to Major Countries |
7.2 Ireland Neuroblastoma Drug Market Imports from Major Countries |
8 Ireland Neuroblastoma Drug Market Key Performance Indicators |
8.1 Patient survival rates post-treatment |
8.2 Adoption rate of innovative neuroblastoma drug therapies |
8.3 Number of clinical trials for neuroblastoma drugs conducted in Ireland |
9 Ireland Neuroblastoma Drug Market - Opportunity Assessment |
9.1 Ireland Neuroblastoma Drug Market Opportunity Assessment, By Mechanism of Action Type, 2021 & 2031F |
9.2 Ireland Neuroblastoma Drug Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.3 Ireland Neuroblastoma Drug Market Opportunity Assessment, By Diagnosis Type, 2021 & 2031F |
9.4 Ireland Neuroblastoma Drug Market Opportunity Assessment, By Treatment Type, 2021 & 2031F |
9.5 Ireland Neuroblastoma Drug Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.6 Ireland Neuroblastoma Drug Market Opportunity Assessment, By End- Users, 2021 & 2031F |
10 Ireland Neuroblastoma Drug Market - Competitive Landscape |
10.1 Ireland Neuroblastoma Drug Market Revenue Share, By Companies, 2024 |
10.2 Ireland Neuroblastoma Drug Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here